Masao Toyoda

List of Publications by Year
in descending order

74 papers	1,825 citations	304368 22 h-index	276539 41 g-index
75 all docs	75 docs citations	75 times ranked	2838 citing authors

#	Article	IF	Citations
1	Podocyte Detachment and Reduced Glomerular Capillary Endothelial Fenestration in Human Type 1 Diabetic Nephropathy. Diabetes, 2007, 56, 2155-2160.	0.3	234
2	Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 951-964.	5.5	228
3	Epithelial-Mesenchymal Transition as a Potential Explanation for Podocyte Depletion in Diabetic Nephropathy. American Journal of Kidney Diseases, 2009, 54, 653-664.	2.1	156
4	A Single Nucleotide Polymorphism within the Acetyl-Coenzyme A Carboxylase Beta Gene Is Associated with Proteinuria in Patients with Type 2 Diabetes. PLoS Genetics, 2010, 6, e1000842.	1.5	81
5	High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney International, 2004, 66, 1107-1114.	2.6	79
6	Association between single nucleotide polymorphisms within genes encoding sirtuin families and diabetic nephropathy in Japanese subjects with type 2 diabetes. Clinical and Experimental Nephrology, 2011, 15, 381-390.	0.7	63
7	Expression of human nephrin mRNA in diabetic nephropathy. Nephrology Dialysis Transplantation, 2004, 19, 380-385.	0.4	62
8	Replication Study for the Association Between Four Loci Identified by a Genome-Wide Association Study on European American Subjects With Type 1 Diabetes and Susceptibility to Diabetic Nephropathy in Japanese Subjects With Type 2 Diabetes. Diabetes, 2010, 59, 2075-2079.	0.3	52
9	Effects of Liraglutide, a Human Glucagon-like Peptide-1 Analogue, on Body Weight, Body Fat Area and Body Fat-related Markers in Patients with Type 2 Diabetes Mellitus. Internal Medicine, 2013, 52, 1029-1034.	0.3	52
10	Relationship between the Expression of Advanced Glycation End-Products (AGE) and the Receptor for AGE (RAGE) mRNA in Diabetic Nephropathy. Internal Medicine, 2006, 45, 435-441.	0.3	48
11	Evaluation of Renal Biopsy Samples of Patients with Diabetic Nephropathy.. Internal Medicine, 2001, 40, 1077-1084.	0.3	44
12	Glomerular expression of platelet-derived growth factor (PDGF)-A, -B chain and PDGF receptor-?, -? in human diabetic nephropathy. Clinical and Experimental Nephrology, 2004, 8, 36-42.	0.7	43
13	Renoprotective effect of long acting thioredoxin by modulating oxidative stress and macrophage migration inhibitory factor against rhabdomyolysis-associated acute kidney injury. Scientific Reports, 2015, 5, 14471.	1.6	40
14	Hypertrophy and Loss of Podocytes in Diabetic Nephropathy. Internal Medicine, 2009, 48, 1615-1620.	0.3	39
15	Expression of Megsin mRNA, a Novel Mesangium-Predominant Gene, in the Renal Tissues of Various Glomerular Diseases. Journal of the American Society of Nephrology: JASN, 1999, 10, 2606-2613.	3.0	39
16	A variant within the FTO confers susceptibility to diabetic nephropathy in Japanese patients with type 2 diabetes. PLoS ONE, 2018, 13, e0208654.	1.1	30
17	Lectin-Like Oxidized LDL Receptor-1 (LOX-1) Expression in the Tubulointerstitial Area Likely Plays an Important Role in Human Diabetic Nephropathy. Internal Medicine, 2009, 48, 189-194.	0.3	29
18	Upregulation of<i>Î±</i>3<i>Î²</i>1-Integrin in Podocytes in Early-Stage Diabetic Nephropathy. Journal of Diabetes Research, 2016, 2016, 1-7.	1.0	27

#	Article	IF	Citations
19	Specific Tissue Distribution of Megsin, a Novel Serpin, in the Glomerulus and Its Up-Regulation in IgA Nephropathy. Biochemical and Biophysical Research Communications, 2001, 286, 1098-1106.	1.0	26
20	A Single Nucleotide Polymorphism in <i>KCNQ1</i> Is Associated With Susceptibility to Diabetic Nephropathy in Japanese Subjects With Type 2 Diabetes. Diabetes Care, 2010, 33, 842-846.	4.3	25
21	Expression of transcription factor Snai1 and tubulointerstitial fibrosis in progressive nephropathy. Journal of Nephrology, 2012, 25, 233-239.	0.9	24
22	Expression of angiotensin II type 1 receptor-interacting molecule in normal human kidney and IgA nephropathy. American Journal of Physiology - Renal Physiology, 2010, 299, F720-F731.	1.3	23
23	The Influence of a Single Nucleotide Polymorphism within CNDP1 on Susceptibility to Diabetic Nephropathy in Japanese Women with Type 2 Diabetes. PLoS ONE, 2013, 8, e54064.	1.1	23
24	Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat MassÂand Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Clinical Drug Investigation, 2019, 39, 631-641.	1.1	21
25	Exercise Therapy for Management of Type 2 Diabetes Mellitus: Superior Efficacy of Activity Monitors over Pedometers. Journal of Diabetes Research, 2016, 2016, 1-7.	1.0	20
26	Expression of Alpha-actinin-4 in Human Diabetic Nephropathy. Internal Medicine, 2008, 47, 1099-1106.	0.3	18
27	Replication study for the association of 3 SNP loci identified in a genome-wide association study for diabetic nephropathy in European type 1 diabetes with diabetic nephropathy in Japanese patients with type 2 diabetes. Clinical and Experimental Nephrology, 2013, 17, 866-871.	0.7	16
28	Predictors of response to liraglutide in Japanese type 2 diabetes. Diabetes Research and Clinical Practice, 2014, 106, 451-457.	1.1	16
29	The Prevalence of 25-hydroxyvitamin D Deficiency in Japanese Patients with Diabetic Nephropathy. Internal Medicine, 2016, 55, 2555-2562.	0.3	15
30	Assessment of the accuracy of an intermittentâ€scanning continuous glucose monitoring device in patients with type 2 diabetes mellitus undergoing hemodialysis (<scp>AIDT2H</scp>) study. Therapeutic Apheresis and Dialysis, 2021, 25, 586-594.	0.4	15
31	Predictive Factors of the Adherence to Real-Time Continuous Glucose Monitoring Sensors: A Prospective Observational Study (PARCS STUDY). Journal of Diabetes Science and Technology, 2021, 15, 1084-1092.	1.3	14
32	Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease. Diabetes and Vascular Disease Research, 2019, 16, 103-107.	0.9	13
33	Genome-wide association studies identify two novel loci conferring susceptibility to diabetic retinopathy in Japanese patients with type 2 diabetes. Human Molecular Genetics, 2021, 30, 716-726.	1.4	13
34	Interaction of the spectrin-like repeats of alpha-actinin-4 with humanin peptide. Clinical and Experimental Nephrology, 2004, 8, 331-338.	0.7	12
35	Effects of Multiple Factorial Intervention on Ambulatory BP Profile and Renal Function in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy â€“ A Pilot Study. Clinical and Experimental Hypertension, 2011, 33, 255-263.	0.5	12
36	Factors affecting consultation length in a Japanese diabetes practice. Diabetes Research and Clinical Practice, 2017, 126, 54-59.	1.1	12

#	Article	IF	Citations
37	Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis. Journal of Nephrology, 2012, 25, 989-995.	0.9	12
38	Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodiumâ€"Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Diabetes Technology and Therapeutics, 2021, 23, 110-119.	2.4	11
39	Clinical Significance of Fibroblast-Specific Protein-1 Expression on Podocytes in Patients with Focal Segmental Glomerulosclerosis. Nephron Clinical Practice, 2012, 120, c1-c7.	2.3	10
40	Glomerular expression of connective tissue growth factor mRNA in various renal diseases. Nephrology, 2003, 8, 92-97.	0.7	9
41	Nivolumabâ€induced fulminant typeÂ1 diabetes with precipitous fall in Câ€peptide level. Journal of Diabetes Investigation, 2020, 11, 748-749.	1.1	9
42	Sodiumâ€"glucose cotransporterÂ2 inhibitorâ€induced reduction in the mean arterial pressure improved renal composite outcomes in typeÂ2 diabetes mellitus patients with chronic kidney disease: A propensity scoreâ€matched model analysis in Japan. Journal of Diabetes Investigation, 2021, 12, 1408-1416.	1.1	9
43	Blood pressure after treatment with sodiumâ€"glucose cotransporterÂ2 inhibitors influences renal composite outcome: Analysis using propensity scoreâ€matched models. Journal of Diabetes Investigation, 2021, 12, 74-81.	1.1	8
44	Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor. Internal Medicine, 2017, 56, 1673-1678.	0.3	7
45	Raltegravir-associated Diabetic Ketoacidosis in a Patient with HIV Infection: A Case Report. Tokai Journal of Experimental and Clinical Medicine, 2018, 43, 19-23.	0.4	7
46	A Liquid-Based Cytology System, without the Use of Cytocentrifugation, for Detection of Podocytes in Urine Samples of Patients with Diabetic Nephropathy. Journal of Diabetes Research, 2019, 2019, 1-7.	1.0	6
47	Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease. Journal of Diabetes Research, 2019, 2019, 1-7.	1.0	6
48	Relationship between Serum Antioxidative Vitamin Concentrations and Type 2 Diabetes in Japanese Subjects. Journal of Nutritional Science and Vitaminology, 2020, 66, 289-295.	0.2	6
49	The Current Intermittent-Scanning CGM Device Situation in Japan: Only Adjunctive Use to SMBG Is Approved and the Latest Health Insurance Coverage Details. Journal of Diabetes Science and Technology, 2018, 12, 729-730.	1.3	5
50	N-Acetyl-seryl-aspartyl-lysyl-proline is a potential biomarker of renal function in normoalbuminuric diabetic patients with eGFRâ€‰â‰¥â€‰30Âml/min/1.73Âm2. Clinical and Experimental Nephrology, 2019, 23, 1004-1012.	0.7	5
51	Development and Validation of the Continuous Subcutaneous Insulin Infusion-Related Quality-of-Life (CSII-QOL) Scale. Diabetes Technology and Therapeutics, 2020, 22, 216-221.	2.4	5
52	The influence of longâ€term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney disease. Journal of Clinical Hypertension, 2020, 22, 2306-2314.	1.0	5
53	Behavior Modification Maintenance with Long-Term Blood Glucose and Weight Management in Praderâ€"Willi Syndrome Complicated with Diabetes: Team Management Approach Combined with Pharmacological Treatment. Case Reports in Medicine, 2019, 2019, 1-7.	0.3	4
54	Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring. Clinical and Experimental Hypertension, 2019, 41, 637-644.	0.5	4

#	Article	IF	Citations
55	Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Diabetes Research and Clinical Practice, 2022, 185, 109231.	1.1	4
56	Interaction of Alpha-Actinin-4 with Class I PxxP Motif-Containing OK/SW-CL.16 Protein. Nephron Experimental Nephrology, 2007, 107, e65-e72.	2.4	3
57	A Retrospective Study on the Efficacy of Corticosteroid-Alone Therapy in Membranous Nephropathy Patients. Internal Medicine, 2007, 46, 1641-1645.	0.3	3
58	Long-Term Intensive Insulin Therapy for Japanese Patients with Type 2 Diabetes Mellitus. Internal Medicine, 2008, 47, 2109-2115.	0.3	3
59	A Case with Membranous Lupus Nephritis Developing after a Twenty-year Remission of Membranoproliferative Glomerulonephritis. Internal Medicine, 2006, 45, 531-536.	0.3	2
60	Clinical comparison of tofogliflozin and empagliflozin based on an analysis of 24-h accumulated urine in Japanese patients with type 2 diabetes mellitus. Obesity Medicine, 2019, 14, 100088.	0.5	2
61	Caution is required for the evaluation of the accuracy of continuous glucose monitoring devices. Journal of Diabetes Investigation, 2020, 11, 255-255.	1.1	2
62	The evaluation of noninferiority for renal composite outcomes between sodiumâ€“glucose cotransporter inhibitors in Japan. Primary Care Diabetes, 2021, 15, 1058-1062.	0.9	2
63	Polypharmacy influences the renal composite outcome in patients treated with sodiumâ€glucose cotransporter 2 inhibitors. Clinical and Translational Science, 2022, , .	1.5	2
64	Favorable Effect on Blood Volume Control in Hemodialysis Patients with Type 2 Diabetes after Switching from Insulin Therapy to Liraglutide, a Human Glucagon-like Peptide-1 Analog--Results from a Pilot Study in Japan-. Tokai Journal of Experimental and Clinical Medicine, 2017, 42, 52-57.	0.4	2
65	Detection of Autonomic Nervous System Abnormalities in Diabetic Patients by 24-hour Ambulatory Blood Pressure Monitoring. Tokai Journal of Experimental and Clinical Medicine, 2018, 43, 97-102.	0.4	2
66	The Effect of High-concentration Insulin Glarigine on the Quality of Life of Patients with Type 2 Diabetes Mellitus: A Pre-post Study (HIGH-QOL STUDY). Internal Medicine, 2019, 58, 2943-2948.	0.3	1
67	Glycemic Control After Kidney Transplantation Using Sensor-augmented Insulin Pump Therapy in a Patient with Slowly Progressive Type 1 Diabetes Mellitus. Tokai Journal of Experimental and Clinical Medicine, 2020, 45, 49-52.	0.4	1
68	Regulation of Blood Pressure and Phosphorylation of Î²1-integrin in Renal Tissue in a Rat Model of Diabetic Nephropathy. Tokai Journal of Experimental and Clinical Medicine, 2021, 46, 172-179.	0.4	1
69	The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Journal of Diabetes Research, 2021, 2021, 1-7.	1.0	1
70	Concomitant treatment with insulin and sodiumâ€glucose cotransporter 2 inhibitors was associated with the renal composite outcome in Japanese patients with type 2 diabetes and chronic kidney disease: A propensity scoreâ€matched analysis. Journal of Diabetes Investigation, 2022, , .	1.1	1
71	Survey of urinary albumin level and estimated GFR in Japanese patients with type 2 diabetes mellitus. Diabetology International, 2013, 4, 101-105.	0.7	0
72	Clinical effects of liraglutide on diabetes control in Japanese type 2 diabetes mellitus patients. Diabetology International, 2014, 5, 98-104.	0.7	0

#	Article	IF	Citations
73	Importance of the Evaluation of Renal Function for the Prevention of Hypoglycemia in Elderly Diabetes Patients. Tokai Journal of Experimental and Clinical Medicine, 2020, 45, 139-143.	0.4	0
74	The Importance of Patient and Family Engagement, the Needs for Self-Monitoring of Blood Glucose (SMBG) â€" Our Perspectives Learned Through a Story of SMBG Assistive Devices Made by a Husband of the Patient with Diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 15, 1627-1638.	1.1	0